危重症患者接受持续低效透析时万古霉素的药代动力学
该研究纳入20例接受持续低效透析(SLED)的少尿或无尿危重症肾衰竭患者,测定万古霉素在SLED期间及之后的药代动力学。结果显示SLED使万古霉素血清浓度降低35.4%,4小时后反弹仅9.8%,提示每次SLED后需追加给药并推荐进行治疗药物监测。
要点
- SLED显著清除万古霉素,血清浓度降低35.4%。
- SLED结束后4小时反弹仅9.8%,无需过度担心。
- 危重症患者每次SLED后需追加万古霉素并做TDM。
核心结论
- 万古霉素在SLED期间被显著清除,SLED结束后4小时血清浓度反弹较小。
- 基于研究结果,危重症患者每次SLED后需追加万古霉素以维持治疗浓度。
- 推荐在SLED期间对万古霉素进行治疗药物监测。
研究设计与样本
- 研究纳入20例接受万古霉素和SLED的少尿或无尿危重症肾衰竭患者。
- 围绕一次SLED session,在SLED开始前、结束时及结束后4小时采血测万古霉素浓度。
- 随后给予万古霉素,目标峰浓度20-30 mcg/ml,输注结束后1小时采血测峰浓度。
- SLED治疗时长至少7小时。
主要发现
- 万古霉素消除速率常数为0.051小时(0.042-0.074小时),半衰期为13.6小时(9.4-16.6小时)。
- SLED使万古霉素血清浓度降低35.4%(31.5-43.8%),反弹为9.8%(2.5-13.7%)。
- SLED后给予的万古霉素剂量为1000 mg(875-1125 mg)。
- 18例患者中,个体化分布容积为0.88 L/kg(0.67-1.1 L/kg),万古霉素清除率为3.5 L/hr(2.2-5.2 L/hr),研究期间浓度-时间曲线下面积为280.8 mg·hr/L(254.7-297.3 mg·hr/L)。
临床怎么用
- 危重症患者接受SLED时,应在每次SLED结束后追加万古霉素剂量。
- SLED期间应开展万古霉素治疗药物监测以指导剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vancomycin pharmacokinetic data in critically ill patients receiving sustained low-efficiency dialysis (SLED) is limited. Published data using vancomycin with intermittent hemodialysis and continuous renal replacement therapy may not be applicable to hybrid dialysis modalities such as SLED. Current drug references lack recommendations for vancomycin dosing in patients receiving SLED. OBJECTIVE: The objective of this study was to determine vancomycin pharmacokinetics during SLED. METHODS: A total of 20 patients who were critically ill with oliguric or anuric renal failure who received vancomycin and SLED were included in the study. Surrounding one SLED session, serum vancomycin blood samples were drawn before the initiation of SLED, at the termination of SLED, and 4 hours after completion of SLED treatment. Following this, patients received vancomycin, dosed to target a goal peak of 20-30 mcg/ml. A vancomycin peak level was drawn 1 hour after the end of the infusion. SLED treatment duration was at least 7 hours. Continuous data are reported as median (interquartile range) and categorical data as percentage. RESULTS: The vancomycin elimination rate and half-life were 0.051 hours (0.042-0.074 hours) and 13.6 hours (9.4-16.6 hours), respectively. SLED reduced vancomycin serum concentrations by 35.4% (31.5-43.8%), and vancomycin rebound was 9.8% (2.5-13.7%). The vancomycin dose administered post-SLED was 1000 mg (875-1125 mg). For 18 patients, the patient-specific volume of distribution was 0.88 L/kg (0.67-1.1 L/kg), vancomycin clearance was 3.5 L/hr (2.2-5.2 L/hr), and the area under the concentration-time curve during the study time period was 280.8 mg·hr/L (254.7-297.3 mg·hr/L). CONCLUSION: Vancomycin is significantly removed during SLED with little rebound in serum concentrations 4 hours after completion of SLED. Based on study findings, patients who are critically ill require additional vancomycin dosing after each SLED session to maintain therapeutic post-SLED vancomycin concentrations. Therapeutic drug monitoring of vancomycin is recommended during SLED.
引用
- Rider TR, Silinskie KM, Hite MS, et al. Pharmacokinetics of Vancomycin in Critically Ill Patients Undergoing Sustained Low-Efficiency Dialysis. Pharmacotherapy. 2020. PMID: 32866291. doi:10.1002/phar.2460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。